Related references
Note: Only part of the references are listed.Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor
S. Verstovsek et al.
ANNALS OF ONCOLOGY (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
Identification of Recurrent FGFR3-TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Marzia Capelletti et al.
CLINICAL CANCER RESEARCH (2014)
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations
Han Kiat Ho et al.
DRUG DISCOVERY TODAY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Justin M. Drake et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations
Howard R. Mellor
LIVER INTERNATIONAL (2014)
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Mitesh J. Borad et al.
PLOS GENETICS (2014)
Oncogenic FGFR3 gene fusions in bladder cancer
Sarah V. Williams et al.
HUMAN MOLECULAR GENETICS (2013)
Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets
Simon Woehrle et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Vito Guagnano et al.
CANCER DISCOVERY (2012)
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
F. R. Lamont et al.
BRITISH JOURNAL OF CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease
Nobuyuki Itoh et al.
JOURNAL OF BIOCHEMISTRY (2011)
Targeting mutant fibroblast growth factor receptors in cancer
Heidi Greulich et al.
TRENDS IN MOLECULAR MEDICINE (2011)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
8p11 myeloproliferative syndrome: a review
Courtney C. Jackson et al.
HUMAN PATHOLOGY (2010)
De-regulated FGF receptors as therapeutic targets in cancer
Victoria Knights et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo
Olivier E. Pardo et al.
CANCER RESEARCH (2009)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target
Margaret A. Knowles
WORLD JOURNAL OF UROLOGY (2007)
Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
D. C. Tomlinson et al.
ONCOGENE (2007)
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
Jorge Sergio Reis-Filho et al.
CLINICAL CANCER RESEARCH (2006)
Cellular signaling by fibroblast growth factor receptors
VP Eswarakumar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
The 8p11 myeloproliferative syndrome: A distinct clinical entity caused by constitutive activation of FGFR1
D Macdonald et al.
ACTA HAEMATOLOGICA (2002)
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4
CD Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
